Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
…, T Berghmans, F Branle, F Lemaitre… - European …, 2001 - Eur Respiratory Soc
The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the
purpose of the present systematic review of the literature is to determine this effect. Published …
purpose of the present systematic review of the literature is to determine this effect. Published …
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
…, T Berghmans, F Branle, JJ Lafitte, F Lemaı̂tre… - Lung cancer, 2000 - Elsevier
Purpose: Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic
drugs for small cell lung cancer (SCLC). The present systematic review had as its objective …
drugs for small cell lung cancer (SCLC). The present systematic review had as its objective …
[HTML][HTML] Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis
B Martin, M Paesmans, T Berghmans, F Branle… - British journal of …, 2003 - nature.com
The role of the anti-apoptotic protein Bcl-2 in lung cancer remains controversial. In order to
clarify its impact on survival in small and non-small cell lung cancer (NSCLC), we performed …
clarify its impact on survival in small and non-small cell lung cancer (NSCLC), we performed …
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 …
…, T McCulloch, P Sen, M Dugan, S Pantano, F Branle… - The Lancet, 2017 - thelancet.com
Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged
non-small-cell lung cancer (NSCLC) is not known. We assessed the …
non-small-cell lung cancer (NSCLC) is not known. We assessed the …
[PDF][PDF] Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with …
…, E Felip, M Nishio, GV Scagliotti, F Branle… - Journal of Clinical …, 2016 - iris.unito.it
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged
non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or …
non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or …
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion …
…, M Stegert, L Wang, FK Hurtado, F Branle… - The Lancet …, 2021 - thelancet.com
Background Several paediatric malignancies, including anaplastic large cell lymphoma (ALCL),
inflammatory myofibroblastic tumour (IMT), neuroblastoma, and rhabdomyosarcoma, …
inflammatory myofibroblastic tumour (IMT), neuroblastoma, and rhabdomyosarcoma, …
ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer …
…, WC Su, T Mok, GV Scagliotti, D Spigel, F Branle… - 2015 - ascopubs.org
8060 Background: Ceritinib demonstrated clinical activity in ALKi-pretreated and -naïve pts
with ALK+ NSCLC, including those with brain metastases (BM; pivotal ASCEND-1 study). …
with ALK+ NSCLC, including those with brain metastases (BM; pivotal ASCEND-1 study). …
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts …
F Branle, F Lefranc, I Camby, J Jeuken… - … Journal of the …, 2002 - Wiley Online Library
… The C6 rat glioma shown in F also exhibited nuclear atypia, mitotic activity, and necrosis (original
magnification, ×200). The photomicrographs in G and H illustrate the immunostaining …
magnification, ×200). The photomicrographs in G and H illustrate the immunostaining …
ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) …
…, T Hida, L Crino, M Nishio, GV Scagliotti, F Branle… - 2015 - ascopubs.org
8059 Background: In the ASCEND-1 study ceritinib showed clinical activity in pts with ALK+
NSCLC, including in brain metastases (BM). ASCEND-2 (NCT01685060) evaluated efficacy …
NSCLC, including in brain metastases (BM). ASCEND-2 (NCT01685060) evaluated efficacy …
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
…, N Boutry, C Broissand, TK Han, F Branle… - Journal of Experimental …, 2022 - rupress.org
… TK Han and F. Branle provided support and performed PK analysis. G. Canaud followed
the patients, provided the conceptual framework, designed the study, supervised the project, …
the patients, provided the conceptual framework, designed the study, supervised the project, …